BMS-214662 (mesylate)

BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. BMS-214662 mesylate exhibits potent antitumor activity and can be utilized in cancer research[1].

Product Specifications

CAS Number

[474010-58-7]

UNSPSC

12352005

Target

Farnesyl Transferase

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

CS(=O)(O)=O.O=S(N(CC1=CC(C#N)=CC=C1N(C2)CC3=CN=CN3)[C@@H]2CC4=CC=CC=C4)(C5=CC=CS5)=O

Molecular Formula

C26H27N5O5S3

Molecular Weight

585.72

References & Citations

[1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.